Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
BMJ Case Rep. 2022 Jul 28;15(7):e247524. doi: 10.1136/bcr-2021-247524.
Thrombotic thrombocytopenic purpura (TTP) is a life-threatening disease that may be triggered by inflammation, including infection or vaccination. Since the start of the COVID-19 pandemic, several case reports were published on de novo or relapsed immune TTP (iTTP) in COVID-19-infected patients. Case reports of iTTP episodes following vaccination against COVID-19 are also emerging. We report a case of relapsed iTTP in a patient who received Moderna mRNA-1273 SARS-CoV-2 vaccine and developed concurrent severe COVID-19 infection. The patient's iTTP was successfully managed with caplacizumab, therapeutic plasma exchange and high-dose steroids. We summarise published cases of iTTP associated with COVID-19 infection or vaccination.
血栓性血小板减少性紫癜（TTP）是一种危及生命的疾病，可能由炎症引发，包括感染或疫苗接种。自 COVID-19 大流行开始以来，已有数篇关于 COVID-19 感染患者新发或复发免疫性 TTP（iTTP）的病例报告。COVID-19 疫苗接种后出现 iTTP 发作的病例报告也在不断出现。我们报告了一例接受 Moderna mRNA-1273 SARS-CoV-2 疫苗后复发 iTTP 的病例，并同时发生严重 COVID-19 感染。该患者的 iTTP 成功地接受了卡替珠单抗、治疗性血浆置换和大剂量类固醇治疗。我们总结了与 COVID-19 感染或疫苗接种相关的 iTTP 病例。
